A Study of TAK-341 in Treatment of Multiple System Atrophy
Phase 2
Completed
NCT05526391
| Condition | Multiple System Atrophy |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 158 participants |
|---|
| Interventions | TAK-341 |
|---|
| Start date | Nov 16, 2022 |
|---|
| Completion date | Jul 28, 2025 |
|---|
| Results posted | Jun 2, 2026 |
|---|
Summary
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
Baseline, Week 52 · score on a scale
| Placebo | 5.58 ± 0.64 score on a scale |
|---|
| TAK-341 | 5.54 ± 0.62 score on a scale |
|---|
| p-value | =0.961 |
|---|
| Least Square (LS) Mean Difference | -0.04 (95% CI -1.78–1.69) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.